CONCORD, Mass.--(BUSINESS WIRE)--N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, is proud to announce the incorporation of the recent AMP guidelines on reporting somatic cancer variants with enhanced levels of evidence (LOE) into N-of-One’s existing curation and reporting. In December of 2016, to address the field’s need for consistent interpretation and reporting of somatic cancer variants from next generation sequencing platforms, the Association for Molecular Pathology (AMP), with liaison representation from the American College of Medical Genetics and Genomics (ACMG), American Society of Clinical Oncology (ASCO), and College of American Pathologists (CAP), released new recommended guidelines for classifying the clinical impact of variants based on diagnostic, prognostic, and treatment predictive evidence.
Powered by a robust proprietary knowledgebase, N-of-One is already recognized as an industry leader for its ability to deliver high-quality, actionable, patient-specific treatment options supported by the latest clinical evidence. With an eye to that leadership, N-of-One has incorporated these variant tiers and enhanced LOEs into their curation and reporting, which will empower key stakeholders to address AMP guidelines without the significant effort that is required to mapping tiers on a case-by-case basis. Further, N-of-One clients will be able to rely on the company’s extensive in-house clinical expertise to categorize variants and maintain tiers and LOEs as the guidelines continue to evolve.
“Inclusion of these guidelines in our reporting was a natural step,” said Chris Cournoyer, Chief Executive Officer of N-of-One, Inc. “For nearly 10 years, our team of oncologist and scientific experts have been refining our curation process to provide the most relevant level of evidence supported by our proprietary software and knowledgebase. The variant tiers defined by AMP will help standardize the reporting in the industry and enable clinicians to better understand the levels of evidence to support their clinical decision making.”
N-of-One is already beginning the implementation process to enhance reporting with its existing clients and partners and the LOE and tier-based reporting is available to new clients. As always, N-of-One’s expert-powered clinical interpretation continues to link each patient's molecular profile with potential treatment strategies, including multiple clinically-relevant features such as clinical trials, multivariant analysis, curation of predictive immunotherapy biomarkers, and prognostic relevance of hematological biomarkers.
“It’s immensely valuable to us to have these tiers included in each patient’s report so soon after the release of the guidelines” said Carlo Bifulco, MD, Medical Director of Oncological Pathology and Pathology Informatics, Providence Healthcare. “As the field evolves, we are confident that we will be able to seamlessly adapt to these new changes and future guidelines, in large part due to our partnership with N-of-One.”
About N-of-One
N-of-One is the leader in identifying
patient-specific therapeutic options for precision medicine in oncology
by leveraging its proprietary knowledgebase and its team of oncologists
and Ph.D. scientists to integrate molecular data from multiple tests.
Using N-of-One solutions can standardize and accelerate genomic clinical
interpretation and molecular decision support while saving time and
money. N-of-One’s solutions have provided therapeutic options, including
clinical trials, for tens of thousands of patient cases across hundreds
of cancer types. N-of-One partners with leading hospital systems, cancer
centers, and commercial labs around the world. For more information,
please visit www.n-of-one.com
or call +1 617-202-9808.
